Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

THE GEORGE INSTITUTE

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Trial of Enhanced Neurostimulation for Anorexia

Not Applicable

Recruiting

Conditions: Anorexia Nervosa

First Posted Date: 2023-03-28

Last Posted Date: 2023-08-07

Lead Sponsor: The George Institute

Target Recruit Count: 70

Registration Number: NCT05788042

Locations: 🇦🇺
Northside Clinic, Sydney, New South Wales, Australia

SMART Health Pregnancy 2 - Intervention to Reduce Anaemia and Cardiometabolic Risk During Pregnancy and in the First Year Following Birth

Not Applicable

Recruiting

Conditions: Pre-Eclampsia
Type 2 Diabetes
Hypertension
Anemia
Anemia of Pregnancy
Gestational Diabetes
Gestational Hypertension

Interventions: Other: SMARThealth Pregnancy

First Posted Date: 2023-03-03

Last Posted Date: 2023-03-03

Lead Sponsor: The George Institute

Target Recruit Count: 3240

Registration Number: NCT05752955

Locations: 🇮🇳
The George Institute for Global Health, Hyderabad, Telangana, India

Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis

Phase 3

Not yet recruiting

Conditions: Diabetic Ketoacidosis

Interventions: Drug: 0.9% sodium chloride
Drug: Plasma-Lyte 148

First Posted Date: 2023-03-02

Last Posted Date: 2024-01-18

Lead Sponsor: The George Institute

Target Recruit Count: 680

Registration Number: NCT05752279

Locations: 🇦🇺
Royal North Shore Hospital, St Leonards, New South Wales, Australia
🇦🇺
Redcliffe Hospital, Redcliffe, Queensland, Australia

PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care

Phase 3

Recruiting

Conditions: Acute Kidney Injury

Interventions: Drug: Dapagliflozin 10mg Tab
Drug: Placebo

First Posted Date: 2022-07-21

Last Posted Date: 2023-12-01

Lead Sponsor: The George Institute

Target Recruit Count: 3000

Registration Number: NCT05468203

Locations: 🇦🇺
Grampians Health, Ballarat, Victoria, Australia
🇦🇺
Austin Health, Heidelberg, Victoria, Australia

TESTING -ON Post-Trial ObservatioNal Cohort Study

Recruiting

Conditions: ESRD
Glomerulonephritis
Kidney Diseases
IgA Nephropathy

First Posted Date: 2022-06-28

Last Posted Date: 2025-02-11

Lead Sponsor: The George Institute

Target Recruit Count: 366

Registration Number: NCT05434325

Locations: 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China
🇨🇳
The Second Hospital of Shanxi Medical University, Taiyuan, Taiyuan, Shanxi, China

and more 55 locations

The RAFT ECT Study

Not Applicable

Recruiting

Conditions: Major Depressive Episode

Interventions: Procedure: Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy
Procedure: Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy

First Posted Date: 2022-06-02

Last Posted Date: 2025-04-11

Lead Sponsor: The George Institute

Target Recruit Count: 154

Registration Number: NCT05402657

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Medical College of Georgia, Augusta University, Augusta, Georgia, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

and more 4 locations

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

Phase 3

Recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Metformin
Drug: Dapagliflozin

First Posted Date: 2022-04-25

Last Posted Date: 2024-12-20

Lead Sponsor: The George Institute

Target Recruit Count: 994

Registration Number: NCT05345327

Locations: 🇦🇺
The George Institute for Global Health, Brisbane, Queensland, Australia
🇦🇺
Monash University, Melbourne, Victoria, Australia
🇱🇰
National Hospital - Galle, Galle, Southern Province, Sri Lanka

and more 4 locations

Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial

Phase 4

Terminated

Conditions: Heart Failure With Preserved Ejection Fraction

Interventions: Drug: Low dose combination polydiuretic therapy
Drug: Comparator monotherapy empagliflozin

First Posted Date: 2021-11-22

Last Posted Date: 2024-11-21

Lead Sponsor: The George Institute

Target Recruit Count: 3

Registration Number: NCT05129722

Locations: 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺
St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia

Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy

Phase 3

Active, not recruiting

Conditions: Neurocognitive Impairment, Mild

Interventions: Other: Standard Care
Drug: Atorvastatin

First Posted Date: 2021-05-27

Last Posted Date: 2025-04-10

Lead Sponsor: The George Institute

Target Recruit Count: 190

Registration Number: NCT04904536

Locations: 🇦🇺
The George Institute for Global Health, Sydney, New South Wales, Australia

Fludrocortisone Dose Response Relationship in Septic Shock - FluDReSS

Phase 2

Completed

Conditions: Critically Ill
Septic Shock

Interventions: Drug: Fludrocortisone Acetate
Other: Standard Therapy

First Posted Date: 2020-07-31

Last Posted Date: 2024-01-18

Lead Sponsor: The George Institute

Target Recruit Count: 155

Registration Number: NCT04494789

Locations: 🇦🇺
Blacktown Hospital, Sydney, New South Wales, Australia
🇦🇺
Royal North Shore Hospital, Sydney, New South Wales, Australia
🇦🇺
Royal Brisbane Women's Hospital, Brisbane, Queensland, Australia

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy